WallStSmart
XBIT

XBiotech Inc

NASDAQ: XBIT · HEALTHCARE · BIOTECHNOLOGY

$2.47
+0.00% today

Updated 2026-06-05

Market cap
$71.34M
P/E ratio
P/S ratio
12.23x
EPS (TTM)
$-1.31
Dividend yield
52W range
$2 – $4
Volume
0.0M

XBiotech Inc (XBIT) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item20122013201420152016201720182019202020212022202320242025
Total assets$8.47M$11.07M$62.18M$109.36M$67.05M$62.97M$44.34M$816.88M$353.74M$275.18M$246.10M$226.62M$199.09M$150.08M
Cash & equivalents$4.17M$7.24M$57.33M$91.05M$34.32M$31.77M$15.82M$714.59M$237.37M$236.98M$157.31M$200.02M$172.68M$125.55M
Current assets$4.36M$7.69M$58.06M$93.04M$36.93M$33.33M$17.02M$716.26M$325.88M$246.87M$219.84M$201.72M$174.57M$126.95M
Total liabilities$1.10M$845000.00$3.15M$6.31M$7.99M$2.81M$2.95M$61.25M$5.11M$5.79M$5.70M$7.77M$16.82M$9.73M
Current liabilities$1.07M$845000.00$3.15M$6.29M$7.96M$2.79M$2.94M$60.19M$3.98M$3.45M$4.07M$6.10M$15.11M$7.93M
Long-term debt$0.00$0.00$0.00
Shareholder equity$7.37M$10.23M$59.03M$103.05M$59.06M$60.16M$41.40M$755.63M$348.64M$269.38M$240.40M$218.85M$182.27M$140.35M
Retained earnings$-61.52M$-71.44M$-93.17M$-130.65M$-183.41M$-216.56M$-237.70M$430.93M$97.57M$5.15M$-27.75M$-52.31M$-90.84M$-136.38M
Accounts receivable$0.00$4.11M$8.95M$1.76M$935000.00$858000.00$360000.00
Inventory$0.00$0.00$0.00$-6.57M$-8.95M
Goodwill$0.00$0.00$0.00

Frequently asked questions

What is XBiotech Inc's revenue?

XBiotech Inc's trailing twelve-month revenue is $300000.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How much free cash flow does XBIT generate?

XBIT produced $-40.21M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is XBIT's balance sheet healthy?

XBIT holds $125.55M in cash and equivalents against — in long-term debt, on $140.35M of shareholder equity. That debt is best read against the cash flow the business throws off each year.